Google · Wired
AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
Compiled by KHAO Editorial — aggregated from 1 outlet. See llms.txt for citation guidance.
◌ Single Source
Google DeepMind’s AlphaFold has already revolutionized scientists’ understanding of proteins.
Key facts
- That changed in 2020, when DeepMind’s Hassabis and John Jumper presented stunning results from AlphaFold 2, which uses deep-learning techniques
- In 2024, DeepMind and Isomorphic Labs released AlphaFold 3, which advanced scientists’ understanding of proteins even further
- Since its release, the AlphaFold platform has been able to predict the structure of virtually all the 200 million proteins known to researchers and has been used by more than 2 million people
- We're gearing up to go into the clinic,” Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London
Summary
Isomorphic Labs, the UK-based biotech spinoff of Google DeepMind, will soon begin human trials of drugs designed by its Nobel Prize–winning AI technology. Jaderberg did not elaborate on the timeline, but it’s later than the company had planned to initiate human studies. Isomorphic Labs was founded in 2021 as a spinoff from Alphabet’s AI research subsidiary, Google DeepMind. Built from 20 different amino acids, proteins are essential for all living organisms. That changed in 2020, when DeepMind’s Hassabis and John Jumper presented stunning results from AlphaFold 2, which uses deep-learning techniques.